IVAICVLGMED-PHJun 7, 2023

Unpaired Deep Learning for Pharmacokinetic Parameter Estimation from Dynamic Contrast-Enhanced MRI

arXiv:2306.04339v11 citationsh-index: 67
Originality Incremental advance
AI Analysis

This addresses the challenge of time and resource constraints in medical imaging for clinicians, though it is incremental as it builds on existing CycleGAN approaches.

The paper tackled the problem of estimating pharmacokinetic parameters from DCE-MRI without paired labeled data, using an unpaired deep learning method based on a physics-driven CycleGAN, which produced more reliable parameters than other techniques.

DCE-MRI provides information about vascular permeability and tissue perfusion through the acquisition of pharmacokinetic parameters. However, traditional methods for estimating these pharmacokinetic parameters involve fitting tracer kinetic models, which often suffer from computational complexity and low accuracy due to noisy arterial input function (AIF) measurements. Although some deep learning approaches have been proposed to tackle these challenges, most existing methods rely on supervised learning that requires paired input DCE-MRI and labeled pharmacokinetic parameter maps. This dependency on labeled data introduces significant time and resource constraints, as well as potential noise in the labels, making supervised learning methods often impractical. To address these limitations, here we present a novel unpaired deep learning method for estimating both pharmacokinetic parameters and the AIF using a physics-driven CycleGAN approach. Our proposed CycleGAN framework is designed based on the underlying physics model, resulting in a simpler architecture with a single generator and discriminator pair. Crucially, our experimental results indicate that our method, which does not necessitate separate AIF measurements, produces more reliable pharmacokinetic parameters than other techniques.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes